1783-P: HM17321, a CRFR2 Selective UCN2 Analog, Prevents Muscle Loss and Functional Decline in Sarcopenic Mice
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-1783-p ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von DAHAE LEE und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: Sarcopenia is characterized by progressive deterioration of skeletal muscle mass, structural integrity and function. Senescence-accelerated mouse-prone 8 (SAMP8) mice represent accelerated aging model that recapitulates key features of sarcopenia. HM17321 is a CRFR2-selective UCN2 analog with established metabolic benefits and emerging relevance to skeletal muscle health. This study evaluated the effects of HM17321 on aging-associated sarcopenia in SAMP8 mice and its efficacy across complementary models of muscle atrophy.
Methods
Male SAMP8 mice were subcutaneously administrated with HM17321 for 4 months, with senescence-resistant SAMR1 mice as age-matched controls. Body composition, neuromuscular function and aging-associated pheontypes were longitudinally assessed. Skeletal muscle atrophy was evaluated by histological analysis. The efficacy of HM17321 against muscle wasting was further assessed in a dexamethasone-induced muscle atrophy model.
Results
Relative to SAMR1 mice, SAMP8 mice exhibited accelerated skeletal muscle degeneration and function decline. HM17321 broadly ameliorated these age-associated deficits, increasing lean mass (up to +7.9% vs. SAMP8 vehicle) while reducing fat mass (up to -23.0%), with concomitant enhancements in muscle performance, including grip strength and holding impulse, as well as attenuation of kyphosis and hindlimb clasping. These improvements were supported by preserved muscle architecture, with maintained myofiber cross-sectional area and laminin expression, and reduced MuRF1 in the gastrocnemius muscle. Consistently, in a dexamethasone-induced muscle atrophy model, HM17321 mitigated functional impairment more effectively than bimagrumab, supporting its protective effect on skeletal muscle under catabolic conditions.
Conclusion
HM17321 attenuated sarcopenia across multiple etiologies by preserving muscle mass, function, and structural integrity. These findings support the potential of HM17321 as a therapeutic approach for sarcopenia. Disclosure D. Lee: None. Y. Kim: None. H. Kwon: Employee; Current; Hanmi Pharm. Co., Ltd. E. Park: Employee; Current; Hanmi Pharm. Co., Ltd. J. Kim: Employee; Current; Hanmi Pharm. Co., Ltd. J. Kim: None. S. Bae: None. S. Lee: Employee; Current; Hanmi Pharm. Co., Ltd. I. Choi: None.
Zitieren
APA
LEE, D., KIM, Y., KWON, H., PARK, E., KIM, J. A., KIM, J. K., BAE, S., LEE, S. H., & CHOI, I. Y. (2026). 1783-P: HM17321, a CRFR2 Selective UCN2 Analog, Prevents Muscle Loss and Functional Decline in Sarcopenic Mice. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1783-p
Vancouver
LEE D, KIM Y, KWON H, PARK E, KIM JA, KIM JK, et al. 1783-P: HM17321, a CRFR2 Selective UCN2 Analog, Prevents Muscle Loss and Functional Decline in Sarcopenic Mice. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1783-p
BibTeX
@article{LEE2026,
author = {LEE, DAHAE and KIM, YOHAN and KWON, HYUNJOO and PARK, EUNJIN and KIM, JEONG A and KIM, JUNG KUK and BAE, SUNGMIN and LEE, SANG HYUN and CHOI, IN YOUNG},
title = {1783-P: HM17321, a CRFR2 Selective UCN2 Analog, Prevents Muscle Loss and Functional Decline in Sarcopenic Mice},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-1783-p}
}
EUVIMED